- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Coiled Therapeutics - Presentation at 18th Annual World Cancer Congress | 2 | RNS | ||
| 08.04. | IN BRIEF: Coiled Therapeutics shares jump as hails inhibitor benefit | 1 | Alliance News | ||
| 08.04. | Coiled Therapeutics - Clinical Trial Update | - | RNS | ||
| 27.03. | Roquefort springs over to AIM from Main Market as Coiled Therapeutics | 2 | Alliance News | ||
| 27.03. | Roquefort Therapeutics plc - Removal | 253 | Dow Jones News | DJ Roquefort Therapeutics plc - Removal
Financial Conduct Authority (-)
Roquefort Therapeutics plc - Removal
27-March-2026 / 08:00 GMT/BST
=----------------------------------------------------------------------------------------------------------------------... ► Artikel lesen | |
| 27.03. | Stock Exch Notice - Readmission - Roquefort Therapeutics Plc | 5 | RNS | ||
| 27.03. | Coiled Therapeutics startet nach Kapitalerhöhung über 8,5 Mio. Pfund am AIM | 5 | Investing.com Deutsch | ||
| 27.03. | Coiled Therapeutics begins trading on AIM after £8.5m raise | 4 | Investing.com | ||
| COILED THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 27.03. | XFRA NEW INSTRUMENTS AVAILABLE ON 27.03.2026 | 421 | Xetra Newsboard | The following instruments on XETRA do have their first trading 27.03.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 27.03.2026
Aktien
1 SE0006887451 Corline Biomedical AB
2... ► Artikel lesen | |
| 26.03. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 26.03.2026 | 570 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 26.03.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 26.03.2026.ISIN NameCA2568277834 DOLLY... ► Artikel lesen | |
| 26.03. | XFRA ISIN CHANGE | 360 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA62821U1003 Mustang Energy Corp. 26.03.2026 CA6279311089 Mustang Energy Corp. 27.03.2026 Tausch 1:1CA28489D1024 Electric... ► Artikel lesen | |
| 26.03. | Roquefort Theraptcs. - Investor Presentation | - | RNS | ||
| 26.03. | Roquefort Theraptcs. - Result of General Meeting | 1 | RNS | ||
| 26.03. | XFRA CAPITAL ADJUSTMENT INFORMATION - 26.03.2026 | 396 | Xetra Newsboard | Das Instrument SU1N CH0008038389 SWISS PRIME SITE SF 2 EQUITY wird cum Kapitalmassnahme gehandelt am 26.03.2026 und ex Kapitalmassnahme am 27.03.2026 The instrument SU1N CH0008038389 SWISS PRIME SITE... ► Artikel lesen | |
| 25.03. | Roquefort Theraptcs. - Lyramid SPA & MK Cell License Update | - | RNS | ||
| 02.03. | AIM - Schedule One - Roquefort Therapeutics PLC | - | RNS | ||
| 02.03. | Roquefort Theraptcs. - Proposed Acquisition and Fundraise of £8.5 million | - | RNS | ||
| 25.02. | Roquefort Theraptcs. - Transaction Update & Notice of Intention to Delist | 1 | RNS | ||
| 15.01. | Roquefort Theraptcs. - Research Note Published | 2 | RNS | ||
| 12.12.25 | Roquefort Theraptcs. - Clinical Trial & License Agreement Update | 3 | RNS |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERA THERAPEUTICS | 43,450 | -2,10 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| EDGEWISE THERAPEUTICS | 33,700 | +1,78 % | Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs | - CIRRUS-HCM 12-week data of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) expected in H1 2026 -
- Phase 1 healthy adult trial... ► Artikel lesen | |
| ARCELLX | 115,00 | +0,10 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| NURIX THERAPEUTICS | 16,970 | +4,11 % | Piper Sandler reiterates Nurix stock rating on CLL drug outlook | ||
| ALUMIS | 24,160 | +5,59 % | H.C. Wainwright reiterates Alumis stock rating, $25 target | ||
| ALLOGENE THERAPEUTICS | 2,165 | -5,04 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation ... | 41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30%MRD Reduction Occurred Rapidly Following Cema-Cel Treatment... ► Artikel lesen | |
| TREVI THERAPEUTICS | 14,270 | +1,64 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates | Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track... ► Artikel lesen | |
| ERASCA | 18,195 | +2,05 % | Jefferies reiterates Erasca stock Buy rating on rival trial data | ||
| MINERALYS THERAPEUTICS | 30,420 | +11,47 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer | RADNOR, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,330 | +5,23 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat | - Matthew Gall appointed Chief Financial Officer -- Additional key appointments add expertise in clinical operations, corporate strategy and project leadership - BOSTON, April 15, 2026 (GLOBE... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,995 | +27,28 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update | Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2 2026 Received FDA clearance to initiate... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 339,71 | -1,02 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor | FDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 18,020 | -4,05 % | H.C. Wainwright reiterates Moonlake stock rating on HS potential | ||
| DYNE THERAPEUTICS | 20,000 | +0,81 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1) | - HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 - - 48-week trial will enroll approximately 150 individuals, and first sites are now open for enrollment... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 36,710 | +1,52 % | Rapport Therapeutics, Inc.: Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | RAP-219's lead program demonstrated robust and consistent activity in patients with focal onset seizures (FOS) in Phase 2a trial; initiation of Phase 3 program expected in the second quarter of 2026RAP-... ► Artikel lesen |
Das Unternehmen COILED THERAPEUTICS PLC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,075 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu COILED THERAPEUTICS PLC finden Sie auf Wallstreet Online.